According to the American Diabetes Association, a sodium-glucose cotransporter 2 (SGLT2) inhibitor or glucagon-like peptide 1 (GLP-1) receptor agonist is recommended as part of a comprehensive cardiovascular risk reduction regimen in all patients with type 2 diabetes and established cardiovascular disease. Multiple clinical trials have demonstrated the beneficial effects of SGLT2 inhibitors, including reducing the risk for major adverse cardiovascular events and heart failure hospitalizations. For example, the EMPEROR-Reduced clinical trial demonstrated that empagliflozin may reduce the risk of cardiovascular death by 38% and decline in glomerular filtration rate.
Learn more about cardiovascular disease in type 2 diabetes.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Romesh Khardori. Fast Five Quiz: Type 2 Diabetes and Coronary Heart Disease - Medscape - Apr 24, 2023.